Centre Proposes Mandatory Prior Approval for Prescription Medicine Ads Across Supply Chains

In a decisive move to curb unauthorized drug marketing and prevent the misuse of potent pharmaceuticals, the central government has proposed sweeping amendments to tighten the advertising of prescription medications. The Union Ministry of Health and Family Welfare has released a draft amendment to the Drugs Rules, 1945, expanding strict advertising curbs on medications listed under Schedules H, H1, and X. While promotional restrictions previously targeted pharmaceutical manufacturers, the new framework brings retailers, wholesalers, stockists, and distributors directly into regulatory scope, requiring prior central government approval before any promotional material can be released.Key Revisions to the Drugs Rules, 1945Notified through Gazette Notification GSR 861(E) dated September 28, 2026, the draft proposal follows in-depth deliberations with the Drugs Technical Advisory Board (DTAB):Inclusion of Sub-Rule (22) in Rule 65: The ministry proposes inserting sub-rule (22) under Rule 65 of the Drugs Rules, 1945, ensuring that advertising curbs apply universally to entities licensed to sell, stock, exhibit, offer for sale, or distribute medicines.Closing the Regulatory Loophole: Historically, pharmaceutical manufacturers faced strict advertising prohibitions, but local distributors and wholesale licensees operated outside an explicit legal framework. The revised rule eliminates this gap, bringing the entire pharmaceutical retail and distribution chain under uniform compliance.Which Medicines Fall Under the New Restrictions?The proposed advertising restrictions specifically apply to critical classes of pharmaceuticals that require compulsory medical supervision:Targeted Drug Schedules: Formulations classified under Schedule H, Schedule H1, and Schedule X—which include potent broad-spectrum antibiotics, habit-forming psychotropic substances, and specialized prescription therapeutics—cannot be advertised without prior central clearance.Mitigating Self-Medication Risks: The central administration aims to prevent unauthorized consumer targeting, over-the-counter push marketing, and health complications arising from the unguided consumption of potent prescription drugs.Deliberations and 30-Day Stakeholder Feedback WindowThe policy stems from recommendations made during the 93rd meeting of the Drugs Technical Advisory Board held on February 16, 2026, which flagged the urgent need to monitor advertising practices across commercial distribution channels:Public Notice: The Ministry of Health and Family Welfare has formally invited objections, feedback, and suggestions from stakeholders, pharmaceutical bodies, and the public.Timeline for Objections: Feedback can be submitted within 30 days from the date the draft notification was made available to the public in the official Gazette, after which the government will review submissions and finalize the statutory amendments.